8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 24, 2026·SEC
Material company update
Mar 13, 2026·SEC
Xenetic Biosciences, Inc.(XBIO)Earnings, Financials & Key Ratios
XBIO•NASDAQ
Price updated Jun 19, 2026
AboutXenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.Show more
- Revenue$3M+19.0%
- EBITDA-$3M+30.0%
- Net Income-$3M+32.3%
- EPS (Diluted)-1.58+38.5%
- Gross Margin100%
- EBITDA Margin-95.23%+41.2%
- Operating Margin-95.23%+43.4%
- Net Margin-90.07%+43.1%
- ROE-40%+20.2%
XBIO Key Insights
Xenetic Biosciences, Inc. (XBIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 24.5%
- ✓Strong 5Y sales CAGR of 46.8%
- ✓Trading at only 0.6x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 10.4% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when XBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XBIO Price & Volume
Xenetic Biosciences, Inc. (XBIO) stock price & volume — 10-year historical chart
Loading chart...
XBIO Growth Metrics
Xenetic Biosciences, Inc. (XBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years46.78%
3 Years20.36%
TTM23.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM39.1%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM48.32%
Return on Capital
10 Years-77.67%
5 Years-42.7%
3 Years-44.68%
Last Year-42.3%
XBIO Recent Earnings
Xenetic Biosciences, Inc. (XBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (82%)●Beat Revenue 7/12 qtrs (64%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.20
—
Rev
$806,923
—
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.22+57.7%
$0.52
Rev
$766,296+11.1%
$690,000
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.33+32.7%
$0.49
Rev
$1M+63.0%
$630,000
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.45+29.7%
$0.64
Rev
$589,897+23.2%
$479,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.20 | $806,923 |
| Q2 2026 | Mar 12, 2026 | $0.22vs $0.52+57.7% | $766,296vs $690,000+11.1% |
| Q4 2025 | Nov 12, 2025 | $0.33vs $0.49+32.7% | $1Mvs $630,000+63.0% |
| Q3 2025 | Aug 12, 2025 | $0.45vs $0.64+29.7% | $589,897vs $479,000+23.2% |
Based on last 12 quarters of dataView full earnings history →
XBIO Peer Comparison
Xenetic Biosciences, Inc. (XBIO) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 ADMA | 1.93B | 8.31 | 13.85 | 19.63% | 32.43% | 38.97% | 0.17 | |
 IMUX | 140.13M | 14.20 | -2.28 | -220.75% | ||||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 CRIS | 81.52M | 0.42 | -0.73 | -13.43% | -299.66% | -138.81% | 0.30 | |
 PRTA | 467.51M | 8.93 | -1.97 | -92.84% | -260.92% | -49.88% | 0.05 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 |
Compare XBIO vs Peers
Xenetic Biosciences, Inc. (XBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XBIO Income Statement
Xenetic Biosciences, Inc. (XBIO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 7.58M | 0 | 17.07K | 436.94K | 1.16M | 1.71M | 2.54M | 2.5M | 2.98M | 3.19M |
Revenue Growth % | 152.83% | -100% | - | 2460.31% | 165.64% | 47.06% | 48.8% | -1.56% | 19.04% | 23.52% |
Cost of Goods Sold | 156.12K | 15.83K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | 2.06% | - | - | - | - | - | - | - | - | - |
Gross Profit | 7.43M▲ 0% | -15.83K▼ 100.2% | 17.07K▲ 207.8% | 436.94K▲ 2460.3% | 1.16M▲ 165.6% | 1.71M▲ 47.1% | 2.54M▲ 48.8% | 2.5M▼ 1.6% | 2.98M▲ 19.0% | 2.38M▲ 0% |
Gross Margin % | 97.94% | - | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 74.71% |
Gross Profit Growth % | 150.68% | -100.21% | 207.83% | 2460.31% | 165.64% | 47.06% | 48.8% | -1.56% | 19.04% | - |
Operating Expenses | 11M | 7.28M | 12.9M | 14.37M | 6.91M | 8.42M | 7.06M | 6.7M | 5.81M | 5.58M |
OpEx % of Revenue | 144.99% | - | 75611.71% | 3289.82% | 595.12% | 493.57% | 277.78% | 268.16% | 195.23% | - |
Selling, General & Admin | 6.94M | 4.39M | 4.73M | 3.4M | 3.74M | 3.65M | 3.56M | 3.42M | 2.75M | 2.74M |
SG&A % of Revenue | 91.47% | - | 27722.82% | 778.15% | 322.56% | 214.07% | 140.2% | 136.64% | 92.24% | - |
Research & Development | 4.06M | 2.88M | 4.89M | 1.73M | 3.16M | 4.77M | 3.49M | 3.29M | 3.07M | 2.85M |
R&D % of Revenue | 53.53% | - | 28649.6% | 396.26% | 272.55% | 279.5% | 137.59% | 131.52% | 102.99% | - |
Other Operating Expenses | -41.1K | -24.64K | 3.28M | 9.24M | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -3.57M▲ 0% | -7.28M▼ 103.9% | -12.89M▼ 77.1% | -13.94M▼ 8.2% | -5.75M▲ 58.8% | -6.72M▼ 16.9% | -4.52M▲ 32.8% | -4.2M▲ 6.9% | -2.83M▲ 32.6% | -2.39M▲ 0% |
Operating Margin % | -47.05% | - | -75511.71% | -3189.82% | -495.12% | -393.57% | -177.78% | -168.16% | -95.23% | -75.05% |
Operating Income Growth % | 92.48% | -103.89% | -77.11% | -8.15% | 58.77% | -16.9% | 32.78% | 6.89% | 32.58% | - |
EBITDA | -3.54M | -7.26M | -12.86M | -13.91M | -5.71M | -6.69M | -4.52M | -4.05M | -2.83M | -2.41M |
EBITDA Margin % | -46.74% | - | -75350.65% | -3183.22% | -492.06% | -391.98% | -177.78% | -162.03% | -95.23% | -75.47% |
EBITDA Growth % | 92.52% | -104.81% | -77.11% | -8.16% | 58.94% | -17.15% | 32.51% | 10.29% | 30.03% | 37.93% |
D&A (Non-Cash Add-back) | 23.78K | 15.83K | 27.49K | 28.84K | 35.48K | 27.04K | 0 | 153.34K | 0 | -13.24K |
EBIT | -3.59M | -7.28M | -9.6M | -4.69M | -5.75M | -6.72M | -4.52M | -4.2M | -2.83M | -2.36M |
Net Interest Income | 14.73K | 0 | 108.49K | 126.17K | 100.47K | 167.15K | 355.76K | 249.86K | 148K | 154.56K |
Interest Income | 16.54K | 0 | 108.49K | 126.17K | 100.47K | 167.15K | 355.76K | 249.86K | 148K | 154.56K |
Interest Expense | 1.82K | 24.13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -26.37K | -24.13K | 111.8K | 125.68K | 101.59K | 165.56K | 381.14K | 244.15K | 153.72K | 160.19K |
Pretax Income | -3.6M▲ 0% | -7.3M▼ 103.1% | -12.78M▼ 75.0% | -13.81M▼ 8.1% | -5.65M▲ 59.1% | -6.55M▼ 16.1% | -4.13M▲ 36.9% | -3.96M▲ 4.2% | -2.68M▲ 32.3% | -2.23M▲ 0% |
Pretax Margin % | -47.4% | - | -74856.59% | -3161.06% | -486.36% | -383.87% | -162.78% | -158.39% | -90.07% | -70.03% |
Income Tax | 26.37K | 24.13K | 0 | -2.92M | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.73% | -0.33% | 0% | 21.13% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -3.6M▲ 0% | -7.3M▼ 103.1% | -12.78M▼ 75.0% | -10.89M▲ 14.7% | -5.65M▲ 48.2% | -6.55M▼ 16.1% | -4.13M▲ 36.9% | -3.96M▲ 4.2% | -2.68M▲ 32.3% | -2.23M▲ 0% |
Net Margin % | -47.4% | - | -74856.59% | -2493.11% | -486.36% | -383.87% | -162.78% | -158.39% | -90.07% | -70.03% |
Net Income Growth % | 93.37% | -103.07% | -74.99% | 14.73% | 48.18% | -16.07% | 36.9% | 4.22% | 32.31% | 39.1% |
Net Income (Continuing) | -3.6M | -7.3M | -12.78M | -10.89M | -5.65M | -6.55M | -4.13M | -3.96M | -2.68M | -2.23M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -49.78▲ 0% | -96.57▼ 94.0% | -55.92▲ 42.1% | -17.04▲ 69.5% | -5.39▲ 68.4% | -4.49▲ 16.7% | -2.71▲ 39.6% | -2.57▲ 5.2% | -1.58▲ 38.5% | -0.98▲ 0% |
EPS Growth % | 94.31% | -93.99% | 42.09% | 69.53% | 68.37% | 16.7% | 39.64% | 5.17% | 38.52% | 48.32% |
EPS (Basic) | -49.78 | -96.58 | -55.92 | -17.04 | -5.39 | -4.49 | -2.71 | -2.57 | -1.58 | - |
Diluted Shares Outstanding | 72.21K | 75.6K | 285.25K | 639.24K | 1.03M | 1.42M | 1.53M | 1.54M | 1.7M | 2.29M |
Basic Shares Outstanding | 72.21K | 75.59K | 285.25K | 639.24K | 1.03M | 1.42M | 1.53M | 1.54M | 1.7M | 2.29M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
XBIO Balance Sheet
Xenetic Biosciences, Inc. (XBIO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 5.88M | 1.19M | 11.09M | 12.37M | 18.72M | 13.65M | 9.59M | 6.59M | 8.05M | 7.6M |
Cash & Short-Term Investments | 5.53M | 571.61K | 10.37M | 11.53M | 18.24M | 13.1M | 8.98M | 6.17M | 7.88M | 7.35M |
Cash Only | 5.53M | 571.61K | 10.37M | 11.53M | 18.24M | 13.1M | 8.98M | 6.17M | 7.88M | 7.35M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 99.51K | 66.51K | 527.08K | 0 | 227.04K | 0 | 603.83K | 0 | 166.29K | 247.81K |
Total Non-Current Assets | 13.28M | 13.24M | 10.46M | 809.99K | 1.09M | 1.07M | 1.02M | 313.92K | 313.92K | 313.92K |
Property, Plant & Equipment | 27.85K | 4.96K | 20.8K | 27.04K | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | 272.39x | - | 0.82x | 16.16x | - | - | - | - | - | - |
Goodwill | 3.28M | 3.28M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 9.24M | 9.24M | 9.24M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 724.71K | 705.66K | 1.19M | 782.94K | 1.09M | 1.07M | 1.02M | 313.92K | 313.92K | 313.92K |
Total Assets | 19.16M▲ 0% | 14.43M▼ 24.7% | 21.55M▲ 49.3% | 13.18M▼ 38.8% | 19.82M▲ 50.3% | 14.72M▼ 25.7% | 10.61M▼ 28.0% | 6.9M▼ 34.9% | 8.36M▲ 21.2% | 7.91M▲ 0% |
Asset Turnover | 0.40x | - | 0.00x | 0.03x | 0.06x | 0.12x | 0.24x | 0.36x | 0.36x | 0.48x |
Asset Growth % | -8.63% | -24.7% | 49.31% | -38.83% | 50.35% | -25.71% | -27.96% | -34.92% | 21.19% | -19.99% |
Total Current Liabilities | 1.94M | 1.6M | 1.42M | 936.93K | 1.42M | 1.07M | 809.59K | 894.26K | 968.02K | 958.24K |
Accounts Payable | 786.78K | 934.15K | 931.13K | 327.4K | 362.47K | 287.36K | 240.83K | 283.62K | 258.11K | 558.81K |
Days Payables Outstanding | 1.84K | 21.54K | - | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 20.04K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 44.31K | 218.03K | 463.99K | 0 | 0 | 39.95K | 48.26K | 34.2K | 709.92K | 399.43K |
Current Ratio | 3.03x | 0.75x | 7.84x | 13.20x | 13.18x | 12.72x | 11.84x | 7.37x | 8.32x | 7.93x |
Quick Ratio | 3.03x | 0.75x | 7.84x | 13.20x | 13.18x | 12.72x | 11.84x | 7.37x | 8.32x | 7.93x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 2.92M | 2.92M | 2.92M | 27.04K | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 27.04K | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 2.92M | 2.92M | 2.92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4.86M | 4.52M | 4.33M | 963.97K | 1.42M | 1.07M | 809.59K | 894.26K | 968.02K | 958.24K |
Total Debt | 0 | 0 | 20.04K | 62.52K | 27.04K | 0 | 0 | 0 | 0 | 0 |
Net Debt | -5.53M | -571.61K | -10.35M | -11.47M | -18.22M | -13.1M | -8.98M | -6.17M | -7.88M | -7.35M |
Debt / Equity | - | - | 0.00x | 0.01x | 0.00x | - | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 3.05x |
Interest Coverage | -1976.52x | -301.53x | - | - | - | - | - | - | - | - |
Total Equity | 14.3M▲ 0% | 9.91M▼ 30.7% | 17.21M▲ 73.6% | 12.22M▼ 29.0% | 18.39M▲ 50.6% | 13.65M▼ 25.8% | 9.8M▼ 28.2% | 6.01M▼ 38.7% | 7.4M▲ 23.1% | 6.95M▲ 0% |
Equity Growth % | -11.55% | -30.69% | 73.65% | -29.03% | 50.58% | -25.81% | -28.22% | -38.67% | 23.12% | -25.22% |
Book Value per Share | 198.04 | 131.12 | 60.35 | 19.11 | 17.89 | 9.59 | 6.41 | 3.90 | 4.35 | 3.03 |
Total Shareholders' Equity | 14.3M | 9.91M | 17.21M | 12.22M | 18.39M | 13.65M | 9.8M | 6.01M | 7.4M | 6.95M |
Common Stock | 9.04K | 9.73K | 6.09K | 8.77K | 13.46K | 1.52K | 1.54K | 1.54K | 2.29K | 2.29K |
Retained Earnings | -145.93M | -153.23M | -166.01M | -176.9M | -182.55M | -189.1M | -193.23M | -197.19M | -199.88M | -200.33M |
Treasury Stock | -5.28M | -5.28M | -5.28M | -5.28M | -5.28M | -5.28M | -5.28M | -5.28M | -5.28M | -5.28M |
Accumulated OCI | 253.73K | 253.73K | 253.73K | 253.73K | 253.73K | 253.73K | 253.73K | 253.73K | 253.73K | 253.73K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XBIO Cash Flow Statement
Xenetic Biosciences, Inc. (XBIO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 1.49M | -6.46M | -6.4M | -4.27M | -4.74M | -4.65M | -4.11M | -2.82M | -2.29M | -1.82M |
Operating CF Margin % | 19.7% | - | -37497.97% | -976.6% | -408.21% | -272.23% | -161.98% | -112.69% | -76.83% | - |
Operating CF Growth % | 117% | -532.6% | 1% | 33.32% | -11.03% | 1.93% | 11.46% | 31.52% | 18.84% | 93.96% |
Net Income | -3.6M | -7.3M | -12.78M | -10.89M | -5.65M | -6.55M | -4.13M | -3.96M | -2.68M | -2.23M |
Depreciation & Amortization | 23.78K | 15.83K | 27.49K | 28.84K | 35.48K | 27.04K | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 1.92M | 1.42M | 853.52K | 468.91K | 410.44K | 511.48K | 283.08K | 171.81K | 64.79K | 29.68K |
Deferred Taxes | 0 | 0 | 0 | -2.92M | -24.27K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -126.32K | -5.23K | 6.38M | 9.1M | 24.27K | 1.79M | 0 | 0 | 0 | 27.17K |
Working Capital Changes | 3.27M | -595.68K | -881.52K | -52.45K | 461.19K | -426.69K | -262.73K | 970.98K | 329.42K | 356.12K |
Change in Receivables | 3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 8.18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -8.18K | -343.88K | -227.96K | -378.11K | 457.13K | -347.95K | -263.57K | 84.68K | 73.76K | 290.31K |
Cash from Investing | -9.26K | 22.5K | 2K | 0 | 0 | -500K | 0 | 0 | 0 | 0 |
Capital Expenditures | -9.26K | 0 | 0 | 0 | 0 | -500K | 0 | 0 | 0 | 0 |
CapEx % of Revenue | 0.12% | - | - | - | - | 29.29% | 0% | - | - | 0% |
Acquisitions | 0 | 22.5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 22.5K | 2K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 125 | 1.48M | 16.13M | 5.43M | 11.45M | 0 | 0 | 0 | 4M | 4M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 16.12M | 5.43M | 11.45M | 0 | 0 | 0 | 4M | 4M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -125 | 1.48M | 6.21K | 0 | 3.68K | 0 | 0 | 0 | 0 | 0 |
Net Change in Cash | 1.48M▲ 0% | -4.96M▼ 434.1% | 9.73M▲ 296.1% | 1.16M▼ 88.1% | 6.72M▲ 479.2% | -5.15M▼ 176.6% | -4.11M▲ 20.1% | -2.82M▲ 31.5% | 1.72M▲ 161.0% | 2.18M▲ 0% |
Free Cash Flow | 1.48M▲ 0% | -6.46M▼ 535.3% | -6.4M▲ 1.0% | -4.27M▲ 33.3% | -4.74M▼ 11.0% | -5.15M▼ 8.6% | -4.11M▲ 20.1% | -2.82M▲ 31.5% | -2.29M▲ 18.8% | -1.82M▲ 0% |
FCF Margin % | 19.58% | - | -37497.97% | -976.6% | -408.21% | -301.52% | -161.98% | -112.69% | -76.83% | -57.09% |
FCF Growth % | 116.87% | -535.3% | 1% | 33.32% | -11.03% | -8.63% | 20.06% | 31.52% | 18.84% | 31.54% |
FCF per Share | 20.56 | -85.50 | -22.43 | -6.68 | -4.61 | -3.62 | -2.69 | -1.83 | -1.34 | -0.79 |
FCF Conversion (FCF/Net Income) | -0.42x | 0.89x | 0.50x | 0.39x | 0.84x | 0.71x | 1.00x | 0.71x | 0.85x | 0.82x |
Interest Paid | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XBIO Key Ratios
Xenetic Biosciences, Inc. (XBIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -23.6% | -60.3% | -94.19% | -74.03% | -36.88% | -40.9% | -35.27% | -50.12% | -40% | -39.28% |
Return on Invested Capital (ROIC) | -25.63% | -60.27% | -119.27% | -274.51% | -929.13% | -1385.82% | -497.16% | -964.01% | - | 520.76% |
Gross Margin | 97.94% | - | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 74.71% |
Net Margin | -47.4% | - | -74856.59% | -2493.11% | -486.36% | -383.87% | -162.78% | -158.39% | -90.07% | -70.03% |
Debt / Equity | - | - | 0.00x | 0.01x | 0.00x | - | - | - | - | 0.00x |
Interest Coverage | -1976.52x | -301.53x | - | - | - | - | - | - | - | - |
FCF Conversion | -0.42x | 0.89x | 0.50x | 0.39x | 0.84x | 0.71x | 1.00x | 0.71x | 0.85x | 0.82x |
Revenue Growth | 152.83% | -100% | - | 2460.31% | 165.64% | 47.06% | 48.8% | -1.56% | 19.04% | 23.52% |
Related:XBIO Dividend History·XBIO Revenue History·XBIO Price History·XBIO P/E History·XBIO Financial Ratios·XBIO Institutional Holders
XBIO SEC Filings & Documents
Xenetic Biosciences, Inc. (XBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
XBIO Frequently Asked Questions
Xenetic Biosciences, Inc. (XBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Xenetic Biosciences, Inc. (XBIO) reported $3.2M in revenue for fiscal year 2025. This represents a 987% increase from $0.3M in 2012.
Xenetic Biosciences, Inc. (XBIO) grew revenue by 19.0% over the past year. This is strong growth.
Xenetic Biosciences, Inc. (XBIO) reported a net loss of $2.2M for fiscal year 2025.
Dividend & Returns
Xenetic Biosciences, Inc. (XBIO) has a return on equity (ROE) of -40.0%. Negative ROE indicates the company is unprofitable.
Xenetic Biosciences, Inc. (XBIO) had negative free cash flow of $1.8M in fiscal year 2025, likely due to heavy capital investments.